Dear Editor, Thrombocytopenia in the neonate is often a life-threatening disorder. Adequate clinical management requires a prompt and accurate diagnosis of the underlying pathology. While acquired thrombocytopenia secondary to the use of certain drugs, such as quinine, heparin, nonsteroidal antiinflammatory agents, histamine blockers, and most chemotherapeutic agents, allopurinol and alcohol, idiopathic thrombocytopenic purpura (ITP) or other failures of thrombopoiesis, such as liver cirrhosis or lack of vitamin B12, are common, congenital disorders of platelet production have recently gained increasing attention. With the discovery of the underlying genetic changes, disorders like X-linked macrothrombocytopenia (mutation in GATA-1) or congenital amegakaryocytic thrombocytopenia (mutations in C-MPL) can now be defined on a molecular basis [1]. Children with these disorders usually do not have additional symptoms other than thrombocytopenia. Patients with Jacobsen syndrome, a rare chromosomal disorder with terminal 11q deletion, can present with growth and mental retardation, trigonocephaly, facial dysmorphism (hypertelorism, epicanthus, ptosis, broad nasal bridge, short nose with anteverted nostrils, high arched palate, retrognathia, carp-shaped upper lip, and low-set dysmorphic ears), abnormal brain structures, congenital heart defects, and genitourinary anomalies in addition to thrombocytopenia [2, 3]. Because of its variable expression, Jacobsen syndrome may not be clinically recognized. Symptoms and severity depend on the size of the deleted region [2]. The genes involved were not identified so far. Differential diagnosis of Jacobsen syndrome includes other chromosomal disorders like 3p− syndrome, 9p− syndrome, and partial distal trisomy 3q. Because Jacobsen syndrome is a contiguous gene syndrome, the size of the deleted region of 11q correlates with a defined phenotype [4]. Only thrombocytopenia seems to be present in nearly every case independent of the breakpoint [5, 6]. In this study, we report on a full-term female neonate with petechiae, intracranial bleeding, cardiac defects, and facial dysmorphia. The platelet count was 26,000/μl, and platelets were normal in size. Mild anemia (hemoglobin 9.5 mg/dl) was attributed to previous bleeding, while the white blood and differential count were normal. In the bone marrow, a high number of micromegakaryocytes were noted. To prevent further bleeding, platelet transfusions were administered regularly. At the age of 2 months, the platelet count spontaneously rose to 70,000/μl to normalize within the subsequent months. Fluorescence R-banding, fluorescence in situ hybridization (FISH), and array-comparative genomic hybridization (CGH) from bone marrow samples and peripheral blood were carried out as previously described by Gadzicki et al. [6]. For the FISH analysis, commercially available locusspecific probes for the subtelomeric region of 11q and for the ataxia-telangiectasia locus (ATM) in 11q22–q23 were used (Vysis, Downers Grove, IL, USA). For both probes used, the cut-off level was defined as 10%. Chromosome banding analysis on bone marrow cells of the newborn showed a structural chromosome aberration, most probably a terminal deletion with a breakpoint in Ann Hematol (2006) 85:883–885 DOI 10.1007/s00277-006-0177-2